Delcath Systems reports Q1 EPS 3c, consensus 3c

Reports Q1 revenue $19.8M, consensus $16.83M. “Consistent revenue growth and the continued expansion of active treatment centers represent a strong start to 2025,” said Gerard Michel, Chief Executive Officer of Delcath. “We achieved our first quarter of net income and positive operating cash flow, underscoring the accelerating clinical adoption of HEPZATO for patients with metastatic uveal melanoma. Ongoing dialogue with oncologists and interventional radiologists reinforces the importance of whole-liver treatment for patients with liver-dominant disease. These insights continue to shape our development strategy as we pursue additional indications for HEPZATO.”